This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: revenue 440.69 and profit 51.01 lakh vs year-ago 434.74 and 81.78 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended 30 Sep 2026: revenue from operations was Rs 440.69 lakh versus Rs 434.74 lakh a year earlier, while net profit was Rs 51.01 lakh versus Rs 81.78 lakh. Revenue rose 1.4%, profit fell 37.6%. EBITDA fell to Rs 54.75 lakh from Rs 84.76 lakh; margin narrowed from 19.5% to 12.4%. For the standalone half year ended 30 Sep 2026, revenue was Rs 771.36 lakh, profit Rs 66.70 lakh and operating cash flow positive at Rs 8.28 lakh.
The sharp profit and EBITDA margin decline is negative for earnings sentiment, though positive operating cash flow provides some support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4.36 Cr | ₹4.29 Cr | +1.8% |
| Operating profit | ₹0.46 Cr | ₹0.76 Cr | −38.7% |
| Profit after tax | ₹0.51 Cr | ₹0.82 Cr | −37.6% |
| EBITDA margin | 11.5% | 18.3% | −6.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.